Edition:
United States

Johnson & Johnson (JNJ)

JNJ on New York Consolidated

138.68USD
22 Oct 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$138.68
Open
$138.61
Day's High
$139.26
Day's Low
$138.14
Volume
4,864,342
Avg. Vol
6,407,962
52-wk High
$148.32
52-wk Low
$118.62

Latest Key Developments (Source: Significant Developments)

J&J Sets Quarterly Cash Dividend Of $0.90 Per Share
Thursday, 18 Oct 2018 08:05am EDT 

Oct 18 (Reuters) - Johnson & Johnson ::SETS QUARTERLY CASH DIVIDEND OF $0.90PER SHARE.  Full Article

Health Canada Has Approved Invokana
Wednesday, 17 Oct 2018 07:00am EDT 

Oct 17 (Reuters) - Johnson & Johnson ::HEALTH CANADA HAS APPROVED INVOKANA (CANAGLIFLOZIN) FOR REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE), THE FIRST SGLT2 INHIBITOR IN CANADA TO RECEIVE THIS INDICATION(1).JANSSEN PHARMACEUTICAL SAYS HEALTH CANADA APPROVED INVOKANA (CANAGLIFLOZIN) FOR REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS.  Full Article

Genmab Q3 Net Sales of Darzalex (Daratumumab) at $498 Mln
Tuesday, 16 Oct 2018 06:45am EDT 

Oct 16 (Reuters) - Genmab ::REG-GENMAB ANNOUNCES NET SALES OF DARZALEX® (DARATUMUMAB) FOR THIRD QUARTER OF 2018.NET SALES OF DARZALEX IN Q3 OF 2018 TOTALED USD 498 MILLION.WILL RECEIVE ROYALTIES ON WORLDWIDE NET SALES FROM JANSSEN BIOTECH, INC..GROWTH WAS PARTIALLY OFFSET BY A ONE-TIME ADJUSTMENT OUTSIDE U.S. RELATED TO ACCRUALS FOR RETROACTIVE PRICING ADJUSTMENTS.ADJUSTMENTS NEGATIVELY IMPACTED THIS WORLDWIDE OPERATIONAL GROWTH BY 16 PERCENTAGE POINTS..2018 Q3 NET SALES WERE USD 318 MILLION IN U.S. AND USD 180 MILLION IN REST OF WORLD..  Full Article

Prime Therapeutics Inks Value-Based Contract For Stelara® With Janssen
Thursday, 4 Oct 2018 10:30am EDT 

Oct 4 (Reuters) - Prime Therapeutics::PRIME THERAPEUTICS INKS VALUE-BASED CONTRACT FOR STELARA® WITH JANSSEN.PRIME THERAPEUTICS - MEDICAL & PHARMACY CLAIMS DATA WILL TRACK HOW LONG PATIENTS STAY ON STELARA, INFORMING CO'S CLINICAL PROGRAMS.  Full Article

Geron Announces Discontinuation Of Imetelstat Collaboration By Janssen
Thursday, 27 Sep 2018 06:00am EDT 

Sept 27 (Reuters) - Geron Corp ::GERON ANNOUNCES DISCONTINUATION OF IMETELSTAT COLLABORATION BY JANSSEN.GERON CORP - GERON PLANS TO INITIATE PHASE 3 PORTION OF IMERGE.GERON CORP - GERON PLANS TO INITIATE PHASE 3 PORTION OF IMERGE.GERON CORP - REGAINS GLOBAL RIGHTS TO IMETELSTAT PROGRAM.GERON CORP - EFFECTIVE DATE OF TERMINATION IS SEPTEMBER 28, 2018.GERON - TRANSITION OF IMETELSTAT PROGRAM TO GERON IS EXPECTED TO OCCUR OVER APPROXIMATELY 12 MONTHS WITH OPERATIONAL SUPPORT FROM JANSSEN.GERON - JANSSEN IS EXPECTED TO SUPPLY IMETELSTAT TO GERON FOR UP TO 24 MONTHS DURING TRANSITION PERIOD FOR CLINICAL MANUFACTURING.GERON CORP - REVISED ITS FINANCIAL PROJECTIONS AND NOW ANTICIPATES 2018 OPERATING EXPENSES TO BE APPROXIMATELY $37 MILLION.GERON CORP - PLANS TO INITIATE PHASE 3 PORTION OF IMERGE AFTER SPONSORSHIP OF ONGOING IMETELSTAT CLINICAL TRIALS TRANSFERRED FROM JANSSEN TO CO.GERON CORP - ANTICIPATES PATIENT SCREENING AND ENROLLMENT FOR PHASE 3 PORTION OF IMERGE TO BEGIN BY MID-YEAR OF 2019.GERON CORP - HAS ENGAGED A GLOBAL CONTRACT RESEARCH ORGANIZATION (CRO) TO SUPPORT IMETELSTAT CLINICAL DEVELOPMENT.GERON-AS OF AUG 31, HAD ABOUT $183 MILLION IN CASH, MARKETABLE SECURITIES; EXPECTED TO BE SUFFICIENT TO SUPPORT PLANS TO INITIATE PHASE 3 OF IMERGE IN 2019.GERON - EXPECTS FINAL DATA FROM PHASE 2 PORTION OF IMERGE TO BE AVAILABLE IN 2019.  Full Article

Janssen Pharmaceutical Says Tremfya Improves Long-Term Patient-Reported Outcomes for Plaque Psoriasis
Wednesday, 12 Sep 2018 08:00am EDT 

Sept 12 (Reuters) - Johnson & Johnson ::JANSSEN PHARMACEUTICAL SAYS TREMFYA IMPROVES LONG-TERM PATIENT-REPORTED OUTCOMES IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS.JANSSEN SAYS DATA SHOW IMPROVEMENTS IN LONG-TERM OUTCOMES IN PATIENTS SWITCHED TO GUSELKUMAB AFTER INADEQUATE RESPONSE TO TREATMENT WITH ADALIMUMAB.  Full Article

Abbvie Announces Imbruvica Plus Rituximab Approval By U.S. FDA For A Rare Type Of Blood Cancer
Monday, 27 Aug 2018 07:00am EDT 

Aug 27 (Reuters) - AbbVie Inc ::ABBVIE ANNOUNCES IMBRUVICA® (IBRUTINIB) PLUS RITUXIMAB APPROVAL BY U.S. FDA AS FIRST CHEMOTHERAPY-FREE COMBINATION TREATMENT IN ADULTS WITH WALDENSTRÖM'S MACROGLOBULINEMIA, A RARE TYPE OF BLOOD CANCER.ABBVIE INC - IMBRUVICA NOW HAS A TOTAL OF NINE FDA APPROVALS ACROSS SIX DIFFERENT DISEASES.ABBVIE INC - FDA APPROVED IMBRUVICA (IBRUTINIB) PLUS RITUXIMAB FOR TREATMENT OF ADULT PATIENTS WITH A TYPE OF NON-HODGKIN'S LYMPHOMA.  Full Article

Johnson & Johnson Announces Chris Delorefice As Vice President Of Investor Relations
Wednesday, 8 Aug 2018 05:30pm EDT 

Johnson & Johnson ::JOHNSON & JOHNSON ANNOUNCES CHRIS DELOREFICE AS VICE PRESIDENT OF INVESTOR RELATIONS.J&J - APPOINTMENT OF CHRIS DELOREFICE TO VICE PRESIDENT OF INVESTOR RELATIONS FOR JOHNSON & JOHNSON, EFFECTIVE AUGUST 13, 2018.  Full Article

CERENOVUS Receives European Regulatory Approval For Bravo Flow Diverter To Treat Intracranial Aneurysms
Wednesday, 8 Aug 2018 10:06am EDT 

Aug 8 (Reuters) - CERENOVUS::CERENOVUS RECEIVES EUROPEAN REGULATORY APPROVAL FOR BRAVO FLOW DIVERTER TO TREAT INTRACRANIAL ANEURYSMS..CERENOVUS SAYS HAS RECEIVED EUROPEAN CE MARK APPROVAL FOR ITS BRAVO FLOW DIVERTER, WHICH IS CURRENTLY NOT APPROVED FOR USE IN UNITED STATES.  Full Article

Johnson & Johnson Consumer Announces Agreement To Acquire Zarbee's Inc
Monday, 30 Jul 2018 07:00am EDT 

July 30 (Reuters) - Johnson & Johnson ::JOHNSON & JOHNSON CONSUMER INC. ANNOUNCES AGREEMENT TO ACQUIRE ZARBEE'S, INC., A LEADER IN NATURALLY-BASED HEALTHCARE PRODUCTS.JOHNSON & JOHNSON CONSUMER INC - FINANCIAL TERMS OF TRANSACTION WERE NOT DISCLOSED.JOHNSON & JOHNSON CONSUMER INC - DEAL WILL INCLUDE FULL LINE OF ZARBEE'S NATURALS PRODUCTS.  Full Article

Judge rejects J&J bid to move Illinois talc case to federal court

A federal judge in Illinois has rejected Johnson & Johnson's bid to transfer a lawsuit alleging its talc products caused a woman's ovarian cancer to federal from state court.